Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COR-101 in Hospitalized Moderate to Severe COVID-19 Patients
NCT04674566Phase 2Unknown
- Sponsor
- CORAT Therapeutics GmbH
- Start
- Apr 2021
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of COR-101 in coronavirus disease 2019 (COVID-19), sponsored by CORAT Therapeutics GmbH. Status: unknown.
02
Drugs
COR-101
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04674566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04674566.